Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Paclitaxel, and Radiation for Pancreatic Cancer
NCT00226746Phase 2Withdrawn
- Sponsor
- NewYork-Presbyterian Brooklyn Methodist Hospital
- Start
- Mar 2003
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by NewYork-Presbyterian Brooklyn Methodist Hospital. Planned start Mar 2003; status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00226746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226746.